Gaucher disease management encompasses enzyme replacement therapy, substrate reduction therapy, supportive care, and emerging therapies. Treatment approach depends on disease type, severity, and organ involvement.
The standard of care for Type 1 Gaucher disease:
- Recombinant glucocerebrosidase administered via IV infusion
- Typical dose: 60 units/kg every 2 weeks
- Effectively reduces liver/spleen size, improves anemia and thrombocytopenia
- Does not cross blood-brain barrier - limited CNS benefit
- Well-tolerated with infusion-related reactions in ~15% of patients
Alternative ERT option:
- Human-derived glucocerebrosidase (not recombinant)
- Same dosing regimen as imiglucerase
- May be preferred for patients with antibody reactions to imiglucerase
Plant-cell derived ERT:
- FDA-approved for adults with Type 1 Gaucher disease
- Lower cost alternative
- Same efficacy and safety profile
Oral SRT for adults with Type 1 Gaucher disease:
- Inhibits glucosylceramide synthase
- Dosed twice daily
- Requires CYP2D6 genotyping - poor metabolizers should not use
- Avoid in patients with cardiac QT prolongation
Oral SRT option:
- Used when ERT is not available or not tolerated
- Lower efficacy than ERT
- GI side effects common (diarrhea, flatulence)
- May have some CNS penetration - potential for neuropathic effects
- No approved therapy crosses blood-brain barrier effectively
- Supportive care for seizures, spasticity, developmental delay
- Multidisciplinary approach including neurology, genetics, rehabilitation
- Physical therapy, occupational therapy, speech therapy as indicated
- Gene therapy approaches in clinical trials
- Small molecule chaperones (e.g., ambroxol) under investigation
- Substrate reduction therapy with CNS-penetrant compounds in development
- Regular monitoring of blood counts
- Iron supplementation if anemic
- Platelet transfusions for severe thrombocytopenia
- Bone density monitoring and treatment
- Bisphosphonates for osteoporosis
- Joint replacement surgery for advanced disease
- Physical therapy for mobility
- Now rarely needed due to effective ERT
- May be considered for severe splenomegaly unresponsive to therapy
¶ Monitoring and Follow-up
- Complete blood count every 3-6 months
- Liver/spleen volume by MRI annually
- Bone density (DEXA) scan annually
- Chitotrioside and glucosylsphingosine biomarkers
- Quality of life assessments
- Normalize hemoglobin and platelet counts
- Reduce liver/spleen volume to <1.5x normal
- Eliminate bone crises
- Maintain normal bone mineral density
- Achieve normal growth in children
- Continue ERT throughout pregnancy - safe and recommended
- May adjust dosing based on disease activity
- Multidisciplinary care with maternal-fetal medicine
- ERT initiated as soon as diagnosis confirmed
- Dosing based on body weight
- Growth and developmental monitoring essential